Home / Market News / $BIVI
fiscal.ai Corporate Catalyst Impact 65/100 ● neutral

BioVie Announces New Clinical and Biomarker Findings from Phase 2 ADDRESS-LC Trial of Bezisterim

Nov 16, 2026, 2:14 PM UTC · Primary ticker $BIVI

BioVie announced new clinical and biomarker findings from its Phase 2 ADDRESS-LC trial of bezisterim, identifying distinct Long COVID endotypes and a reduction in neuropeptide Y levels. This data suggests potential efficacy for bezisterim in treating Long COVID, which could positively impact the company's future prospects.

BioVie announced new clinical and biomarker findings from its Phase 2 ADDRESS-LC trial of bezisterim for Long COVID. The key findings include the identification of two distinct biomarker-defined Long COVID endotypes that responded differently to treatment, and a reduction in neuropeptide Y levels with bezisterim. This is significant because it provides further evidence of bezisterim's potential efficacy and offers insights into patient stratification, which could improve future trial designs and treatment targeting. For BioVie, this positive data could enhance investor confidence and potentially lead to further development and commercialization opportunities for bezisterim, representing a short-term positive catalyst and long-term growth opportunity. The primary risk is that these Phase 2 findings may not translate to successful outcomes in larger, later-stage trials.

$BIVI positive Positive clinical trial data for key drug candidate
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.